^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
HLX55
i
Other names: HLX55, HLX-55, KTN0216, KTN 0216, humanized IgG2 monoclonal antibody
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Fosun Pharma
Drug class:
c-MET inhibitor
Related drugs:
over4years
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status (clinicaltrials.gov)
P1, N=98, Recruiting, Henlix, Inc | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
|
HLX55
almost5years
Evaluate Safety, Tolerability and PK of HLX55 in Patients With Advanced Solid Tumors With Different cMET Status (clinicaltrials.gov)
P1, N=98, Not yet recruiting, Henlix, Inc | Initiation date: Nov 2019 --> Apr 2020
Clinical • Trial initiation date
|
KRAS (KRAS proto-oncogene GTPase) • MET (MET proto-oncogene, receptor tyrosine kinase)
|
MET amplification • MET exon 14 mutation • MET overexpression • MET mutation
|
HLX55
Share via
